Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study.

ABSTRACT:

Background

The United States Preventive Services Task Force supports individualised decision-making for prostate-specific antigen (PSA)-based screening in men aged 55-69. Knowing how the potential benefits and harms of screening vary by an individual's risk of developing prostate cancer could inform decision-making about screening at both an individual and population level. This modelling study examined the benefit-harm tradeoffs and the cost-effectiveness of a risk-tailored screening programme compared to age-based and no screening.

Methods and findings

A life-table model, projecting age-specific prostate cancer incidence and mortality, was developed of a hypothetical cohort of 4.48 million men in England aged 55 to 69 years with follow-up to age 90. Risk thresholds were ba

SUBMITTER: Callender T 

PROVIDER: S-EPMC6924639 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature